V. Guidelines during Treatment
Immune/Antibody
W
View full entry on WUSTL Neuromuscular
antibody/mag.html#V. Guidelines during Treatment
Overview
From WUSTL NeuromuscularAim for reduction of antibody titer to 30% of initial level. Serial titers help to determine Appropriate duration and dose of immunosuppressive treatment. Likelihood of efficacy A rise in anti-MAG titer after treatment may predict recurrence of clinical symptoms and signs. References
Related Conditions
Shared genesAntibodies vs Glycolipids & Glycoproteins
GM1MAGGQ1B
Axonal Sensory Neuropathies with Serum IgM binding to Trisulfated Heparin Disaccharide (TS-HDS)
HDSDISACCHARIDEMAG
I. Clinical Indications for Measurement of anti-MAG antibodies
MAG
II. Results with Specificity and Sensitivity for Sensory-Motor Neuropathies
MAG
III. Testing Laboratory Standards for anti-MAG Antibodies.
MAG
IV. Interpretations of Confirmed Positive anti-MAG Results
MAG
IV. Positive Result: Clinical Utility and Interpretations
MAG
Monoclonal Gammopathies of Unknown Significance (& Other)
MAGGD1AHDS
External Resources
Data sourced from the Washington University Neuromuscular Disease Center. For clinical use, always refer to primary sources.